These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19500496)

  • 21. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Schwartz GG; Chaitman BR; Goldberger JJ; Messig M
    Am Heart J; 2011 May; 161(5):993-9. PubMed ID: 21570534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
    Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
    Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
    Szarek M; Amarenco P; Callahan A; DeMicco D; Fayyad R; Goldstein LB; Laskey R; Sillesen H; Welch KM;
    J Am Coll Cardiol; 2020 May; 75(17):2110-2118. PubMed ID: 32194196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Goldstein LB; Amarenco P; Zivin J; Messig M; Altafullah I; Callahan A; Hennerici M; MacLeod MJ; Sillesen H; Zweifler R; Michael K; Welch A;
    Stroke; 2009 Nov; 40(11):3526-31. PubMed ID: 19745172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins and stroke: current clinical practice.
    Castilla-Guerra L; Espino-Montoro A; Fernandez Moreno Mdel C; López-Chozas JM; Jimérnez MD
    Stroke; 2006 May; 37(5):1153. PubMed ID: 16556875
    [No Abstract]   [Full Text] [Related]  

  • 30. Expanding roles for atorvastatin.
    Singh V; Deedwania P
    Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin therapy after stroke or transient ischemic attack.
    Elkind MS
    N Engl J Med; 2006 Nov; 355(22):2369; author reply 2370-1. PubMed ID: 17139774
    [No Abstract]   [Full Text] [Related]  

  • 32. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Amarenco P; Benavente O; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; Gilbert S; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2009 Apr; 40(4):1405-9. PubMed ID: 19228842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke--an equal opportunity for the initiation of statin therapy.
    Kent DM
    N Engl J Med; 2006 Aug; 355(6):613-5. PubMed ID: 16899782
    [No Abstract]   [Full Text] [Related]  

  • 34. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
    ; Karam JG; Loney-Hutchinson L; McFarlane SI
    J Cardiometab Syndr; 2008; 3(1):68-9. PubMed ID: 18326981
    [No Abstract]   [Full Text] [Related]  

  • 36. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
    Arca M; Gaspardone A
    Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of intensive treatment with atorvastatin versus standard doses of statins on the risk of stroke. A meta-analysis from five randomized trials including 25,709 patients].
    Fernándezde Bobadilla J; Moreno R; Fernández C; Martínez A; Sánchez-Maestre C; Ezpeleta-Echevarri D
    Rev Neurol; 2009 Jun 1-15; 48(11):561-5. PubMed ID: 19472152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.